Your doctor will determine the appropriate dose for you.
Pregabalin is exclusively for oral use.
Peripheral and central neuropathic pain, epilepsy, or generalized anxiety disorder:
If you estimate that the action of pregabalin is too strong or too weak, inform your doctor or pharmacist.
If you are an elderly patient (over 65 years old), you should take pregabalin normally, except if you have kidney problems.
Your doctor may prescribe another dosing regimen and/or different doses if you have kidney problems.
Swallow the capsule whole with water.
Continue taking pregabalin until your doctor tells you to stop.
If you take more Pregabalin Mabo than you should
Call your doctor or go to the nearest emergency service immediately. Bring the pregabalin package with you. As a result of taking more pregabalin than you should, you may feel drowsy, confused, agitated, or restless.Also, seizures and loss of consciousness (coma) have been reported.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicological Information Service, phone: 91 562 04 20, indicating the medication and the amount ingested.
If you forgot to take Pregabalin Mabo
It is essential to take the pregabalin capsules regularly at the same hour every day. If you forget to take a dose, take it as soon as you remember, unless it is time for the next dose. In that case, continue with the next dose normally. Do not take a double dose to compensate for the missed doses.
If you interrupt the treatment with Pregabalin Mabo
Do not stop taking Pregabalin abruptly. If you want to stop taking pregabalin, talk to your doctor first. He will tell you how to do it. If you are going to stop treatment, this should be done gradually over a minimum of one week.
Once the treatment with pregabalin is completed, whether it is long-term or short-term, you should know that you may experience certain adverse effects, called withdrawal effects. These include sleep problems, headaches, nausea, anxiety, diarrhea, flu-like symptoms, seizures, nervousness, depression, thoughts of self-harm or suicide, pain, sweating, and dizziness. These effects may appear more frequently or severely if you have been taking pregabalin for a longer period. If you experience withdrawal effects, consult your doctor.
If you have any other doubts about the use of this medication, ask your doctor or pharmacist.
This medication, like all others, may cause side effects, although not everyone will experience them.
Very common: may affect more than 1 in 10 people:
Common: may affect up to 1 in 10 people
Uncommon: may affect up to 1 in 100 people:
Rare: may affect up to 1 in 1,000 people
Very rare: may affect up to 1 in 10,000 people
Frequency not known: cannot be estimated from available data
Once a short- or long-term treatment with Pregabalina has been completed, you should know that you may experience certain side effects, called withdrawal effects (see “If you stop taking Pregabalina”).
If you experience swelling in the face or tongue, or if your skin becomes red and blisters or peels, seek immediate medical assistance.
The following adverse reaction has been reported in post-marketing experience: difficulty breathing, shallow breathing.
Reporting of adverse reactions
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the Spanish System for the Pharmacovigilance of Medicinal Products for Human Use:https://www.notificaram.es.
By reporting adverse reactions, you can contribute to providing more information on the safety of this medication.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the packaging or in the bottle after CAD. The expiration date is the last day of the month indicated.
No special storage conditions are required.
Medications should not be disposed of through drains or in the trash. Dispose of the containers and medications you no longer need at the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of the containers and medications you no longer need. By doing so, you will help protect the environment.
Appearance of the product and contents of the packaging
Thecapsules of this medication are opaque, with a pink cap and a cream-colored body and have "75" engraved.
PVC/Aluminum blisters containing56and100(clinical packaging)hard capsules.
Only some package sizes may be marketed.
Holder of the marketing authorization and responsible for manufacturing
Holder of the marketing authorization
MABO-FARMA, S.A.
Calle Vía de los Poblados, 3, Edificio 6
28033 Madrid,
Spain.
Responsible for manufacturing
Pliva Croatia, Ltd.
Prilaz Baruna Filipovica, 25.
10.000, Zagreb, Croatia.
or
Merckle GmbH,
Ludwig-Merckle Strasse, 3.
D-89143, Blauberen-Weiler, Germany
Revision date of this leaflet:January 2024
The detailed and updated information on this medication is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.